Abstract Number: 1982 • ACR Convergence 2022
Pluripotency Marker PBX1 Predicts Treatment Effect in Rheumatoid Arthritis
Background/Purpose: Self-renewal ability, which is important for the adaptive immunity and adequate T cell function, is severely impaired in rheumatoid arthritis (RA). This leads to…Abstract Number: 2150 • ACR Convergence 2022
Cycling vs Swapping Strategies with TNFi and IL-17i in Psoriatic Arthritis: An Observational Retrospective Monocentric Study
Background/Purpose: The therapy of psoriatic arthritis (PsA) was amplified in the last years with the introduction of a large amount of new biologic molecules with…Abstract Number: 0192 • ACR Convergence 2022
Upadacitinib versus Adalimumab on Routine Assessment of Patient Index Data 3 (RAPID3) in Patients with Psoriatic Arthritis
Background/Purpose: RAPID3 (Routine Assessment of Patient Index Data 3) is a disease activity index calculated from 3 patient-reported measures: physical function, pain, and patient global…Abstract Number: 0308 • ACR Convergence 2022
Risankizumab (RZB) Demonstrates Long-Term Efficacy Across Subgroups in Patients with Active Psoriatic Arthritis (PsA): A Post Hoc, Integrated Analysis from the Phase 3 (KEEPsAKE 1 and KEEPsAKE 2) Studies
Background/Purpose: Risankizumab (RZB), a fully humanized IgG1 monoclonal antibody inhibitor of IL-23, is a therapeutic agent approved for the treatment of active psoriatic arthritis (PsA)…Abstract Number: 0699 • ACR Convergence 2022
Effectiveness by Disease Severity in Patients with Psoriatic Arthritis Treated with Apremilast in the CorEvitas Psoriatic Arthritis/Spondyloarthritis (PsA/SpA) Registry
Background/Purpose: Clinical trials of the efficacy and safety of apremilast have shown a significant therapeutic effect on disease activity across clinically diverse PsA patients. Given…Abstract Number: 0810 • ACR Convergence 2022
Analysis of Factors Associated with Good Therapeutic Response to Immunosuppressive Drugs in Patients with Non-infectious Uveitis: A Survival Analysis
Background/Purpose: Non-infectious uveitis (NIUs) encompass a varied group of inflammatory diseases affecting the uvea and adjacent tissues, with evidence suggesting an immune-mediated cause. A correct…Abstract Number: 0930 • ACR Convergence 2022
Delayed Response to Methotrexate Treatment in Rheumatoid Arthritis Patients Receiving Folic Acid Supplementation
Background/Purpose: MTX is the first line conventional synthetic DMARD (csDMARD) for the treatment of rheumatoid arthritis (RA), and folic acid (FA) supplementation is frequently co-prescribed…Abstract Number: 1289 • ACR Convergence 2022
Evaluating Peri–operative Preferences of Bariatric Surgeons in the Management of Immunosuppressive Therapy During Bariatric Surgery
Background/Purpose: As the number of bariatric procedures increases, surgeons will encounter more patients on long-term immunosuppressive medications that may increase post-operative complications. Currently, there are…Abstract Number: 1613 • ACR Convergence 2022
Diagnostic Delay and Less Intensive Therapy for People with Psoriatic Arthritis Compared with Rheumatoid Arthritis: A Nested Matched Cohort Study from Within the UK National Early Inflammatory Arthritis Audit
Background/Purpose: To compare the time from symptom onset and General Practitioner (GP) presentation to referral and diagnosis for patients with psoriatic arthritis (PsA) to those…Abstract Number: 1983 • ACR Convergence 2022
Anti-S1 Antibody Levels Two Weeks After the Second Dose of an mRNA anti-SARS-CoV2 Vaccine Predict Maintenance of a Potent Neutralizing Activity over 24 Weeks in RA Patients
Background/Purpose: Patients with inflammatory rheumatic diseases (IRD) on immunomodulatory therapies have a higher likelihood of an impaired vaccine-induced immune response following an mRNA anti-SARS-CoV-2 vaccine.…Abstract Number: 2193 • ACR Convergence 2022
Invasive Fungal Diseases in Patients with Autoimmune Diseases: Prospective Data from a Nationwide French Registry
Background/Purpose: Patients with autoimmune diseases (AIDs) display a risk of invasive fungal diseases (IFDs), because of the underlying disease or treatments used. Our objective was…Abstract Number: 0245 • ACR Convergence 2022
Influence of Forced Vital Capacity Impairment on Treatment Selection and Outcomes in RA-ILD Patients Initiating a Biologic or Targeted-Synthetic DMARD
Background/Purpose: Patients with RA-associated interstitial lung disease (RA-ILD) suffer from substantial morbidity and premature mortality. The optimal use of biologic/tsDMARDs in this population is poorly…Abstract Number: 0312 • ACR Convergence 2022
Dose-dependent Suppression of T Cell-Dependent Antibody Response in Healthy Volunteers by KPL-404, an Anti-CD40 Monoclonal Antibody, Supports Phase 2 Study in Patients with Rheumatoid Arthritis
Background/Purpose: An unmet need remains in patients with failure and/or inadequate response (IR) to biological disease-modifying antirheumatic drugs (bDMARD-IR) and/or Janus kinase inhibitors (JAKi-IR). The…Abstract Number: 0705 • ACR Convergence 2022
Severity of SARS-CoV-2 Omicron Breakthrough Infections in Patients with Rheumatic Immune-mediated Inflammatory Diseases and Healthy Controls: Data from a Prospective Cohort Study
Background/Purpose: The Omicron (B.1.1.529) variant of SARS-CoV-2 is associated with substantially lower hospitalization rates compared with previous variants of SARS-CoV-2 (i.e., Wildtype, Alpha [B.1.1.7] and…Abstract Number: 0837 • ACR Convergence 2022
Providers’ Adoption of 2017 Guidelines on DMARD Use Perioperatively for Elective Total Hip and Knee Arthroplasty at a Single Academic Center
Background/Purpose: Rate of prosthetic joint infection (PJI) after total joint arthroplasty (TJA) is higher in patients with rheumatic conditions than in patients with OA. Our…
- « Previous Page
- 1
- …
- 20
- 21
- 22
- 23
- 24
- …
- 40
- Next Page »